Taking Advantage of Generation “Like”: Using Digital Technology and Social Media to Reduce Trial Timelines

Matthew Doscher, Research Analyst
By Matthew Doscher,
Research Analyst

Social media is a dominating force throughout the entire world. Over 2.3 billion people use social network worldwide — that equals 31% of the global population. In the United States, 78% of the population possesses a social network profile. Now an extremely crucial tool, businesses try to find multiple ways to use social media advantageously. The pharmaceutical industry is no exception. Pharma companies look to use these new tools to help expedite trial timelines especially within Phase 4 studies.

Continue reading


Funding an Investigator Sponsored Study? Use Milestone Payments.

Natalie DeMasi, clinical development and medical affairs researcher
By Natalie DeMasi,
Senior Research Analyst

Funding an investigator sponsored study (ISS) is a great opportunity for companies to expand a product’s data portfolio, strengthen relationships with HCPs and demonstrate corporate goodwill.  Despite these benefits, there are some risks to ISS’s.  Namely, the data produced will be tied to the company’s product — regardless of the scientific merit — and the funding provided to the investigator may be open to public scrutiny.  For these reasons, most investigator sponsored study teams will carefully evaluate each research proposal and fund investigators based on milestone payments.

Continue reading


Exploring High and Low Pharma Staffing Levels for Medical Affairs

Natalie DeMasi, clinical development and medical affairs researcher
By Natalie DeMasi,
Senior Research Analyst

Global medical affairs teams come in all shapes and sizes — some comprise a large percentage of pharma staffing, and others a small percentage.  In many cases, the size of a medical affairs team will reflect not only the company’s resources but also its product portfolio.  For instance, companies with mostly early-stage investigational products may not need a large medical affairs force.  Conversely, companies with constant product launches will benefit from a robust team.

Continue reading


Moving Forward with Physician Payment Disclosure Requirements in Scotland

Sarah Ray, regulatory affairs and safety researcher
By Sarah Ray,
Senior Research Analyst

Already, many countries have established physician payment disclosureregulations that require companies to publish any exchanges of value that take place between healthcare practitioners (HCPs) and themselves. In some cases—as with the Loi Bertrand in France—these regulations may also extend to other members of the healthcare community. Beyond HCPs, the Loi Bertrand also covers audiences such as pharmacists, nurses and professional medical associations.

Continue reading


Be On the Lookout for New Innovations in Late Stage Studies

Natalie DeMasi, clinical development and medical affairs researcher
By Natalie DeMasi,
Senior Research Analyst

Teams have a variety of options when conducting a post-marketing study, and these options only increase as researchers continue to innovate new trial designs beyond the standard randomized controlled trial (RCT). For instance, teams may decide to collect real-world data with observational cohort studies. Others may want to directly compare two competing treatments with crossover studies. Alternatively, study teams may try to collect near real-world data with pragmatic RCTs.

Continue reading


Balancing KAM Tasks: How Many Accounts Can One Key Account Manager Handle?

Sarah Ray, regulatory affairs and safety researcher
By Sarah Ray,
Senior Research Analyst

Pharma key account management (KAM) teams focus on strengthening relationships with existing client accounts and forging new ones. As an example, these teams may reach out to hospital systems to determine which products these organizations use (or would be interested in trying). Some life science teams designate specific KAM groups to handle commercial and market access account types. Others make no distinction across the different audiences that dedicated KAM teams may serve.

Continue reading


Recap: Medical Affairs Launch Planning Webinar

Natalie DeMasi, medical affairs launch planning researcher
By Natalie DeMasi,
Senior Research Analyst

Medical affairs is on the front lines of a product launch.  During this crucial launch window, medical information and communication teams are responsible for raising awareness, educating stakeholders and generally laying the groundwork for the product’s success in the healthcare community.  These tasks make medical affairs launch planning a cornerstone of product success.  However, medical affairs teams are only as effective as their planning and preparation, as poor timing or a sub-par strategy can diminish their impact. Continue reading



Shape Up Your Key Account Management Team Engagement Strategies

Victoria Cavicchi, pharmaceutical social media researcher
By Victoria Cavicchi,
Senior Research Analyst

The role of pharma key account management (KAM) is growing.  Throughout the life sciences industry, KAMs act as the voice of the company for major commercial accounts – including physician networks, hospital systems and even payer organizations.  Because a large part of the key account management team role is working directly with these accounts, KAMs may also need to coordinate their visits and discussion topics with other outward-facing teams across the organizations.  In fact, many companies would prefer that KAMs act in a strategic role to shape the organization’s account communication. Continue reading


Where in the World Do MSL Teams Operate?

Natalie DeMasi, clinical development and medical affairs researcher
By Natalie DeMasi,
Senior Research Analyst

Medical science liaisons (MSLs) are the company’s messengers, spreading the word about new data to all the corners of the healthcare industry.  But just how far do those corners extend?  It goes without saying that most companies won’t invest MSL resources in regions where there are few healthcare providers (HCPs) to interact with.  However, companies are busy establishing large MSL teams in new areas with flourishing healthcare industries. Continue reading